KNSA Relative Valuation
KNSA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KNSA is overvalued; if below, it's undervalued.
Historical Valuation
Kiniksa Pharmaceuticals International PLC (KNSA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.78 is considered Undervalued compared with the five-year average of -289.56. The fair price of Kiniksa Pharmaceuticals International PLC (KNSA) is between 2009.27 to 2017.23 according to relative valuation methord. Compared to the current price of 42.03 USD , Kiniksa Pharmaceuticals International PLC is Undervalued By 97.91%.
Relative Value
Fair Zone
2009.27-2017.23
Current Price：42.03
97.91%
Undervalued
27.82
PE
1Y
3Y
5Y
20.12
EV/EBITDA
Kiniksa Pharmaceuticals International PLC. (KNSA) has a current EV/EBITDA of 20.12. The 5-year average EV/EBITDA is -26.41. The thresholds are as follows: Strongly Undervalued below -326.72, Undervalued between -326.72 and -176.56, Fairly Valued between 123.75 and -176.56, Overvalued between 123.75 and 273.90, and Strongly Overvalued above 273.90. The current Forward EV/EBITDA of 20.12 falls within the Historic Trend Line -Fairly Valued range.
20.43
EV/EBIT
Kiniksa Pharmaceuticals International PLC. (KNSA) has a current EV/EBIT of 20.43. The 5-year average EV/EBIT is 1.55. The thresholds are as follows: Strongly Undervalued below -76.00, Undervalued between -76.00 and -37.22, Fairly Valued between 40.33 and -37.22, Overvalued between 40.33 and 79.10, and Strongly Overvalued above 79.10. The current Forward EV/EBIT of 20.43 falls within the Historic Trend Line -Fairly Valued range.
3.78
PS
Kiniksa Pharmaceuticals International PLC. (KNSA) has a current PS of 3.78. The 5-year average PS is 7.33. The thresholds are as follows: Strongly Undervalued below -11.69, Undervalued between -11.69 and -2.18, Fairly Valued between 16.84 and -2.18, Overvalued between 16.84 and 26.35, and Strongly Overvalued above 26.35. The current Forward PS of 3.78 falls within the Historic Trend Line -Fairly Valued range.
-68.47
P/OCF
Kiniksa Pharmaceuticals International PLC. (KNSA) has a current P/OCF of -68.47. The 5-year average P/OCF is 195.42. The thresholds are as follows: Strongly Undervalued below -1876.19, Undervalued between -1876.19 and -840.39, Fairly Valued between 1231.22 and -840.39, Overvalued between 1231.22 and 2267.03, and Strongly Overvalued above 2267.03. The current Forward P/OCF of -68.47 falls within the Historic Trend Line -Fairly Valued range.
47.28
P/FCF
Kiniksa Pharmaceuticals International PLC. (KNSA) has a current P/FCF of 47.28. The 5-year average P/FCF is -31.97. The thresholds are as follows: Strongly Undervalued below -359.29, Undervalued between -359.29 and -195.63, Fairly Valued between 131.69 and -195.63, Overvalued between 131.69 and 295.35, and Strongly Overvalued above 295.35. The current Forward P/FCF of 47.28 falls within the Historic Trend Line -Fairly Valued range.
Kiniksa Pharmaceuticals International PLC (KNSA) has a current Price-to-Book (P/B) ratio of 5.92. Compared to its 3-year average P/B ratio of 3.52 , the current P/B ratio is approximately 68.01% higher. Relative to its 5-year average P/B ratio of 3.70, the current P/B ratio is about 60.15% higher. Kiniksa Pharmaceuticals International PLC (KNSA) has a Forward Free Cash Flow (FCF) yield of approximately 3.20%. Compared to its 3-year average FCF yield of 1.92%, the current FCF yield is approximately 66.85% lower. Relative to its 5-year average FCF yield of -4.27% , the current FCF yield is about -174.77% lower.
5.92
P/B
Median3y
3.52
Median5y
3.70
3.20
FCF Yield
Median3y
1.92
Median5y
-4.27
Competitors Valuation Multiple
The average P/S ratio for KNSA's competitors is 775.29, providing a benchmark for relative valuation. Kiniksa Pharmaceuticals International PLC Corp (KNSA) exhibits a P/S ratio of 3.78, which is -99.51% above the industry average. Given its robust revenue growth of 61.17%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of KNSA increased by 117.76% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 25.95 to 89.98.
The secondary factor is the Revenue Growth, contributed 61.17%to the performance.
Overall, the performance of KNSA in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
AMC
AMC Entertainment Holdings Inc
1.535USD
0.99%
SCS
Steelcase Inc
16.14USD
0.12%
BLBD
Blue Bird Corp
46.94USD
-0.95%
RBCAA
Republic Bancorp Inc
67.8USD
-1.15%
SGML
Sigma Lithium Corp
15.675USD
-3.42%
GEL
Genesis Energy LP
15.34USD
-0.78%
TPC
Tutor Perini Corp
70.985USD
-0.22%
USPH
US Physical Therapy Inc
79.1USD
-2.65%
SILA
Sila Realty Trust Inc
23.09USD
-0.65%
Frequently Asked Questions
Is Kiniksa Pharmaceuticals International PLC (KNSA) currently overvalued or undervalued?
Kiniksa Pharmaceuticals International PLC (KNSA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.78 is considered Undervalued compared with the five-year average of -289.56. The fair price of Kiniksa Pharmaceuticals International PLC (KNSA) is between 2009.27 to 2017.23 according to relative valuation methord. Compared to the current price of 42.03 USD , Kiniksa Pharmaceuticals International PLC is Undervalued By 97.91% .
What is Kiniksa Pharmaceuticals International PLC (KNSA) fair value?
KNSA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Kiniksa Pharmaceuticals International PLC (KNSA) is between 2009.27 to 2017.23 according to relative valuation methord.
How does KNSA's valuation metrics compare to the industry average?
The average P/S ratio for KNSA's competitors is 775.29, providing a benchmark for relative valuation. Kiniksa Pharmaceuticals International PLC Corp (KNSA) exhibits a P/S ratio of 3.78, which is -99.51% above the industry average. Given its robust revenue growth of 61.17%, this premium appears sustainable.
What is the current P/B ratio for Kiniksa Pharmaceuticals International PLC (KNSA) as of Jan 07 2026?
As of Jan 07 2026, Kiniksa Pharmaceuticals International PLC (KNSA) has a P/B ratio of 5.92. This indicates that the market values KNSA at 5.92 times its book value.
What is the current FCF Yield for Kiniksa Pharmaceuticals International PLC (KNSA) as of Jan 07 2026?
As of Jan 07 2026, Kiniksa Pharmaceuticals International PLC (KNSA) has a FCF Yield of 3.20%. This means that for every dollar of Kiniksa Pharmaceuticals International PLC’s market capitalization, the company generates 3.20 cents in free cash flow.
What is the current Forward P/E ratio for Kiniksa Pharmaceuticals International PLC (KNSA) as of Jan 07 2026?
As of Jan 07 2026, Kiniksa Pharmaceuticals International PLC (KNSA) has a Forward P/E ratio of 27.82. This means the market is willing to pay $27.82 for every dollar of Kiniksa Pharmaceuticals International PLC’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Kiniksa Pharmaceuticals International PLC (KNSA) as of Jan 07 2026?
As of Jan 07 2026, Kiniksa Pharmaceuticals International PLC (KNSA) has a Forward P/S ratio of 3.78. This means the market is valuing KNSA at $3.78 for every dollar of expected revenue over the next 12 months.